Prognostic significance of osteopontin expression in gastric cancer: a meta-analysis.
BACKGROUND
Accumulated studies have exploited the association between osteopontin (OPN) expression and survival of patients with gastric cancer (GC), however, the results were controversial. Thus, we performed a meta-analysis, aiming to investigate the prognostic role of OPN for GC patients and to explore the association between OPN and clinicalpathological features of GC.


RESULTS
A total of ten studies involving 1775 patients were included in final meta-analysis. Of the included studies, nine were conducted on Asian patients and one was performed on Caucasian patients. Regarding OPN detection, immunohistochemistry (IHC) was used on tissue specimens in eight studies and enzyme linked immunosorbent assay (ELISA) was used on plasma specimens in two studies. The pooled data showed that high OPN expression was correlated with poor OS (HR = 1.59, 95% CI: 1.15-2.22, p = 0.006). Subgroup analyses demonstrated that OPN had enhanced prognostic value for Asian patients (HR = 1.64, 95% CI = 1.11-2.41, p = 0.012) and for patients receiving surgical resection (HR = 1.6, 95% CI = 1.04-2.48, p = 0.034). In addition, the results also showed that elevated OPN expression was associated with lymph node metastasis, TNM stage, depth of invasion, tumor size and distant metastasis in GC.


METHODS
Relevant studies were retrieved through PubMed, Embase and Web of Science. Combined hazard ratio (HR) and 95% confidence interval (CI) were calculated to assess the association between OPN and overall survival (OS). Subgroup analyses and publication bias were also conducted.


CONCLUSIONS
OPN overexpression was correlated with poor OS and clinical features reflecting high aggressiveness in patients with GC. OPN was a promising prognostic biomarker for GC.
Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
Xiaobin
X
Gu
Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
Xian-Shu
XS
Gao
Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
Mingwei
M
Ma
Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
Shangbin
S
Qin
Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
Xin
X
Qi
Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
Xiaoying
X
Li
Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
Shaoqian
S
Sun
Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
Hao
H
Yu
Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
Wen
W
Wang
Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
Dong
D
Zhou
D000328:Adult; D000368:Aged; D015415:Biomarkers; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D053495:Osteopontin / Q000032:analysis / Q000502:physiology*; D011379:Prognosis; D017594:Publication Bias; D013274:Stomach Neoplasms / Q000401:mortality* / Q000473:pathology
D015415:Biomarkers; D053495:Osteopontin
biomarker; gastric cancer; meta-analysis; osteopontin; prognosis